Investors looking for stocks in the Medical - Products sector might want to consider either ResMed (RMD) or LeMaitre Vascular (LMAT) . But which of these two companies is the best option for those looking for undervalued stocks? Let's take a closer look.We have found that the best way to discover great value opportunities is to pair a strong Zacks Rank with a great grade in the Value category of our Style Scores system. The Zacks Rank is a proven strategy that targets companies with positive earnings estima ...

Growth investors focus on stocks that are seeing above-average financial growth, as this feature helps these securities garner the market's attention and deliver solid returns. But finding a growth stock that can live up to its true potential can be a tough task.By their very nature, these stocks carry above-average risk and volatility. Moreover, if a company's growth story is over or nearing its end, betting on it could lead to significant loss.However, the task of finding cutting-edge growth stocks is mad ...

Core Viewpoint - ResMed Inc. has demonstrated strong growth in the first quarter of fiscal 2025, primarily driven by its Mask business and device sales, although increasing debt levels pose a concern [1][9]. Group 1: Financial Performance - ResMed's shares have increased by 55.4% over the past year, outperforming the industry growth of 23.1% and the S&P 500's rise of 33% [2]. - The company has a market capitalization of $35.10 billion and an earnings yield of 14.8%, which is higher than the industry's 14.4% [2]. - ResMed's earnings have consistently surpassed estimates in the last four quarters, with an average surprise of 6.4% [2]. - The Zacks Consensus Estimate for ResMed's fiscal 2025 earnings has increased by 2.1% to $9.28 per share, with revenues projected at $5.07 billion, reflecting an 8.2% year-over-year increase [10]. Group 2: Business Segments - The Mask business has seen robust sales, benefiting from a competitor's recall and strong global demand, with an 11% year-over-year revenue increase [3][4]. - Device sales have also contributed significantly to revenue growth, with a reported global increase of 10% and 11% in the U.S., Canada, and Latin America [5][6]. - The respiratory care segment is thriving, with ongoing investments in new technologies for chronic obstructive pulmonary disease (COPD) and other respiratory conditions [7][8]. Group 3: Challenges - ResMed's long-term debt stood at $688 million as of September 30, 2024, with cash and cash equivalents of $426.4 million, raising concerns about the sustainability of its debt levels [9].

Investors seek growth stocks to capitalize on above-average growth in financials that help these securities grab the market's attention and produce exceptional returns. But finding a great growth stock is not easy at all.By their very nature, these stocks carry above-average risk and volatility. Moreover, if a company's growth story is over or nearing its end, betting on it could lead to significant loss.However, the Zacks Growth Style Score (part of the Zacks Style Scores system), which looks beyond the tr ...

For new and old investors, taking full advantage of the stock market and investing with confidence are common goals. Zacks Premium provides lots of different ways to do both. The research service features daily updates of the Zacks Rank and Zacks Industry Rank, full access to the Zacks #1 Rank List, Equity Research reports, and Premium stock screens, all of which will help you become a smarter, more confident investor. Zacks Premium includes access to the Zacks Style Scores as well. What are the Zacks Style ...

Shares of ResMed (RMD) have been strong performers lately, with the stock up 7.1% over the past month. The stock hit a new 52-week high of $260.49 in the previous session. ResMed has gained 48.9% since the start of the year compared to the 5.1% move for the Zacks Medical sector and the 12.8% return for the Zacks Medical - Products industry. What's Driving the Outperformance? The stock has a great record of positive earnings surprises, as it hasn't missed our earnings consensus estimate in any of the last fo ...

On Thursday, ResMed Inc RMD reported first-quarter adjusted EPS of $2.20, up 34% year over year, beating the consensus of $2.04. The company reported sales of $1.224 billion, up 11%, beating the consensus of $1.18 billion, driven by increased demand for sleep devices and masks portfolio and strong growth across the Residential Care Software business. Residential Care Software revenue increased by 12% on a constant currency basis, reflecting continued organic growth in the Residential Care Software portfolio ...

Core Insights - ResMed Inc. reported adjusted earnings per share (EPS) of $2.20 for Q1 fiscal 2025, reflecting a 34.1% year-over-year increase and surpassing the Zacks Consensus Estimate by 8.4% [1] - The company's total revenues for the first quarter reached $1.22 billion, marking an 11.1% increase year-over-year and exceeding the Zacks Consensus Estimate by 2.9% [2] Financial Performance - The GAAP EPS for the quarter was $2.11, up 41.6% from the previous year [1] - Adjusted gross profit rose 17.5% to $724.9 million, with an adjusted gross margin of 59.2%, an increase of 324 basis points [5] - Adjusted operating income increased by 27.7% to $406.4 million, with an adjusted operating margin expanding 431 basis points to 33.2% [6] Revenue Breakdown - Revenues from the Sleep and Breathing Health segment improved 11% year-over-year to $1.07 billion, exceeding projections [4] - Global device revenues were $625.8 million, up 11%, while Masks and other revenues reached $442 million, also up 11% [4] - Residential Care Software revenues grew 13% year-over-year to $156.8 million, falling short of expectations [4] Cash and Debt Position - ResMed ended the quarter with cash and cash equivalents of $426.4 million, up from $238.4 million at the end of Q4 fiscal 2024 [7] - Total debt decreased to $677.5 million from $706.2 million at the end of the previous quarter [7] - The company generated cumulative net cash from operating activities of $325.5 million, compared to $286.3 million in the prior year [7] Strategic Developments - ResMed announced the launch of its first fabric mask, the AirTouch N30i, and introduced new patient-centric products aimed at enhancing therapy for sleep apnea patients [9] - The company unveiled its 2030 strategy focused on growth, profitability, and shareholder returns through product innovation and operational excellence [9] Market Reaction - Following the earnings announcement, ResMed's shares increased by 6.1% in after-hours trading [1]

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 ______________________________________________________________________________________________ Title of each class Trading Symbol(s) Name of each exchange on which registered Common Stock, par value $0.004 per share RMD New York Stock Exchange FORM 10-Q ______________________________________________________________________________________________ (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT ...

ResMed (RMD) came out with quarterly earnings of $2.20 per share, beating the Zacks Consensus Estimate of $2.03 per share. This compares to earnings of $1.64 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of 8.37%. A quarter ago, it was expected that this maker of medical products for respiratory disorders would post earnings of $2.03 per share when it actually produced earnings of $2.08, delivering a surprise of 2.46%.Over the ...